93516-44-0

Upstream product

• 57021-26-8 2-amino-6-methoxy-4-phenylpyridine-3,5-dicarbonitrile 

Downstream Products

• 1184935-26-9 2-hydrazinyl-6-methoxy-4-phenylpyridine-3,5-dicarbonitrile 
• 1246269-31-7 3-amino-6-methoxy-4-phenyl-1H-pyrazolo[3,4-b]pyridine-5-carbonitrile 
• 1246269-36-2 4-phenyl-1,7-dihydrodipyrazolo[3,4-b:4',3'-e]pyridine-3,5-diamine 

Relevant academic research and scientific papers

Synthesis and biological evaluation of 3,6-diamino-1H-pyrazolo[3,4-b]pyridine derivatives as protein kinase inhibitors

The synthesis and biological evaluation of a number of differently substituted 3,6-diamino-1H-pyrazolo[3,4-b]pyridine derivatives are reported. From the inhibition results on a selection of disease-relevant protein kinases [IC50 (μM) DYRK1A = 11; CDK5 = 0.41; GSK-3 = 1.5] we have observed that 3,6-diamino-4-phenyl-1H-pyrazolo[3,4-b]pyridine-5-carbonitrile (4) constitutes a potential new and simple lead compound in the search of drugs for the treatment of Alzheimer's disease.

Medicine comprising dicyanopyridine derivative

Compounds having a high conductance-type of calcium-activated K channel opening effect and a smooth muscle relaxant effect for bladder based on the K-channel opening effect, which can be used in treating pollakiuria and urinary incontinence, are provided.